Abstract
We reviewed the experience of a tertiary cancer centre in the management of adrenocortical carcinoma (acc) treated over 40 years. We also searched the literature for guidelines related to the treatment of acc and for evidence for adjuvant radiation therapy (rt). In a retrospective chart review, acc patients treated between January 1974 and December 2013 were identified, and patient demographics and tumour characteristics were extracted. Outcomes data, including dates and sites of failure, vital status, and cause of death, were collected. Overall survival was estimated using the Kaplan- Meier method. A medline search using PubMed, Ovid, and embase was used to review the literature about the role of rt and any available management guidelines for acc. Of 81 patients identified during the chart review, 39 had confirmed acc. In 32 patients, surgical resection was performed, including in 2 patients with M1 disease. Of those 32 patients, 16 received adjuvant systemic treatment (mitotane or concurrent chemoradiation). Only 6 patients received adjuvant rt, of whom 3 are still alive (2 living with distant failure). At a median follow-up of 3.8 years, 28 patients had died (72%), 10 were living (26%), and 1 had been lost to follow-up. Of the 22 patients for whom failure data were available, 2 experienced local failure, and the rest, distant failure. The current data are insufficient to make treatment recommendations. Use of collaborative databases and consensus about diagnostic and therapeutic guidelines are warranted for better identification of optimum management. Adjuvant rt could be a reasonable option for R1 disease, but further research is needed.
Highlights
Adrenocortical carcinoma is a rare disease with an annual incidence of 0.5–2 per million population[1,2]
Adjuvant rt could be a reasonable option for R1 disease, but further research is needed
A study from the MD Anderson Cancer Center reported no benefit[4], and another study from the Ann Arbor Group reported a reduced risk of local recurrence with adjuvant rt in conjunction with mitotane after open laparotomy[5]
Summary
Adrenocortical carcinoma (acc) is a rare disease with an annual incidence of 0.5–2 per million population[1,2]. No randomized controlled trials have been conducted so far. Several international networks, such as the European Network for the Study of Adrenal Tumours, have been developed to establish guidelines for the diagnosis and treatment of the disease. Surgical resection is the main curative treatment for both early and advanced disease; local and distant failures are frequent, and survival is poor[1]. The role of adjuvant radiation therapy (rt) in this disease is ill defined. The first retrospective trial examining the role of rt in the adjuvant setting reported improved local control with rt[3]. Additional consolidated research efforts are needed to address the role of adjuvant rt in acc
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.